Category Archives: Cardiac Regeneration

The partnership dates back to March 2013, when Moderna Therapeutics and AstraZeneca signed a five year exclusive option agreement to apply the companys platform in the search for new ways to treat cardiovascular and other diseases. In preparation for the first in-human safety studies the two companies are now working towards taking a mRNA therapeutic candidate through toxicology studies while addressing further in vivo proof of concept and targeted delivery. Ken and I speak several times a week to keep the programme moving and to discuss novel applications of this fascinating technology, says Dr Fritsche-Danielson. Other significant collaboration partners include the University of Singapore, Shanghai Institute of Biological Sciences and the University of Virginia that all contribute to advancing the programme. The challenge is to keep connected, the field moves fast. Its not just about finding new compounds, you need to think further ahead. At AstraZeneca, we have a good academic collaboration culture, says Dr Gabriella Broln, Senior Scientist in AstraZenecas Discovery Sciences department. Helping the team shed light on the disease by linking patient phenotypes to the different types of heart failure is a collaboration with Singapores Agency for Science, Technology and Research (A*STAR), National University Heart Centre, and … Continue reading →

The UW Department of Bioengineering is excited to announce the recruitment of stem cell expert Jennifer Davis (Cincinnati Childrens Hospital Medical Center) and human tissue engineer Kelly Stevens (Massachusetts Institute of Technology) to our faculty. The new tenure-track assistant professors will join the University of Washingtons world-class team in smart biomaterials, stem cell biotechnology and tissue engineering, creating a powerhouse cluster of faculty in the area of cardiac regeneration research and translation. The Department of Bioengineering, a joint department in the School of Medicine and the College of Engineering, is one of the first bioengineering departments established in the U.S., and has been ranked among the top ten programs in the nation since its inception. The hires are a partnership between UWs Departments of Bioengineering and Pathology with support from the Institute for Stem Cell & Regenerative Medicine, the Center for Cardiovascular Biology and the Division of Cardiology. Both Dr. Davis and Dr. Stevens will have joint tenure-track faculty appointments in Bioengineering and Pathology. Jen and Kelly are rising stars in stem cell and regeneration sciences who will accelerate advancement toward our first-in-human cardiac stem cell clinical trials, part of the Heart Regeneration Program led by Professor of Bioengineering and … Continue reading →

Job: FacultyOrganization: SOM Clinical DepartmentsTitle:Postdoctoral Fellow Research Associate-SurgeryLocation: nullRequisition ID: 17000060 The major focus of our research projects is to determine the mechanism for cardiac regeneration using different cell-based preparations, including exosomes, condition media, and the stem cells themselves and testing these cell-based products in a variety of regenerative assays. In particular, we are determining how mIRs present in the exosomes derived from the stem cells affect the regenerative process to recover the injured myocardium. Several animal and cell model systems, including conditional gene knockouts, will be used in these research projects, and many state of the art techniques are available, such as real time PCR, CRISPR/Cas9 Genome Editing, confocal microscopy,real time imaging and advanced microscopy, multicolor flow and sorting,HPLC and mass spectrometry, and ultrasonic and telemetric measurements of cardiovascular function in rodents and large animals. Applicants must have a PhD, MD/PhD or equivalent degree and proven skills and experience in molecular biology.The University of Maryland School of Medicine has a group of outstanding scientists in cardiovascular research, especially in cardiovascular cell signaling, diabetes, endothelial biology, and pathogenesis of atherosclerosis. Successful applicants will have the opportunity to work with them and get help in developing an independent career in this … Continue reading →

Cardiac Regeneration and Repair, Volume One reviews the pathology of cardiac injury and the latest advances in cell therapy. Chapters in part one explore the pathogenesis of congestive heart failure, the mechanisms responsible for adverse cardiac matrix remodeling, and potential interventions to restore ventricular function. Part two highlights new approaches to cell therapy for cardiac regeneration, and includes chapters covering alternative routes of cell delivery, monitoring cell engraftment, and the feasibility of using allogeneic stem cells to restore cardiac function. Chapters in part three move on to highlight novel stem cells for cardiac repair, including human embryonic stem cells and human pluripotent stem cells, and detail their current status and future potential for cardiac therapy. Finally, part four explores gene therapy, and includes ultrasound-targeted or direct gene delivery as well as cell-based gene therapy for cardiac regeneration. Cardiac Regeneration and Repair, Volume One is complemented by a second volume covering biomaterials and tissue engineering. Together, the two volumes of Cardiac Regeneration and Repair provide a comprehensive resource for clinicians, scientists, or academicians fascinated with cardiac regeneration, including those interested in cell therapy, tissue engineering, or biomaterials. More here: Cardiac regeneration and repair - 1st Edition - Elsevier … Continue reading →

Cardiac (Elias Wirtham) is a fictional character, a vigilante anti-hero appearing in American comic books published by Marvel Comics. Created by writer David Michelinie and penciller Erik Larsen, he first appeared as Elias Wirtham in The Amazing Spider-Man #342 (December 1990)[1] and as Cardiac in The Amazing Spider-Man #344 (February, 1991).[2] Wirtham is a physician and surgeon, and the owner and administrator of a biological research firm. Elias Wirtham is driven by his brother's death to research life-saving medical practices. His brother Joshua's death was the result of corporate greed, who had a cure for his condition ready, but did not distribute the medicine due to it not being a "profitable" time for them, hence his motivation against corporations. As a part of his research, Elias replaces his heart with a beta-particle reactor, which supplies energy throughout his body, in addition to a vibranium weave mesh under his skin. This energy, channeled through his muscles, increases his speed, agility, and reflexes, and can also be fired through his fists or the power staff he wields. He adopts the moniker "Cardiac" in reference to the source of his power.[3] Cardiac becomes a vigilante, believing himself an instrument of justice. He first … Continue reading →

Sessions/Tracks Track 1 : Heart Diseases and Failure Heart diseasesare the disorders that affect the heart.Diseasesunder theheart diseasesumbrella includeblood vessel diseases, such ascoronary arterydisease,heart rhythmproblems(arrhythmias), and heart defects i.e. congenital heart defects,Rheumatic heart disease, Hypertensive heart disease,Ischemic heart disease, Hypertension etc. Heart failureis a condition in which the heart can't pump enough blood to meet the body's needs. The term Heart failure doesnt mean that the heart has stopped its functions. CHD can lead to heart failure by weakening theheart muscleover time. However,heart failureis a serious condition that requires medical care. Related Conferences: 29th World Cardiology Conference November 19-20, 2018 Edinburgh, Scotland; Clinical Cardiology and Cardiovascular Disease May 24-25, 2018 London, UK; 24th World Cardiology Conference 17-18 September,2018 Hong Kong; 27th European Cardiology Conference October 22-24, 2018 Rome, Italy; Global Cardiology Summit October 22-23, 2018 Osaka, Japan; International Heart Conference Singapore City, Singapore August 13-15, 2018; Pediatric Heart Diseases and Pediatric Health October 08-09, 2018 Related Societies: Cardiology Conferences 2018,Cardiology Congress 2018,Upcoming Cardiology Conferences 2018,World Cardiology Conferences2018,Cardiology Conferences USA,Cardiology Conferences Europe, Cardiology Conferences Asia Pacific,Cardiology Conferences Middle East,Heart Congress 2018,Heart Conferences 2018,Cardiologist Meet 2018,Heart Diseases Conferences 2018,Women Cardiology Conferences 2018,Cardiology Nursing Conferences 2018,Sweden Conferences 2018,Hypertension Conferences 2018 America: American Society … Continue reading →

In biology, regeneration is the process of renewal, restoration, and growth that makes genomes, cells, organisms, and ecosystems resilient to natural fluctuations or events that cause disturbance or damage.[1] Every species is capable of regeneration, from bacteria to humans.[2][3] Regeneration can either be complete[4] where the new tissue is the same as the lost tissue,[4] or incomplete[5] where after the necrotic tissue comes fibrosis.[5] At its most elementary level, regeneration is mediated by the molecular processes of gene regulation.[6][7] Regeneration in biology, however, mainly refers to the morphogenic processes that characterize the phenotypic plasticity of traits allowing multi-cellular organisms to repair and maintain the integrity of their physiological and morphological states. Above the genetic level, regeneration is fundamentally regulated by asexual cellular processes.[8] Regeneration is different from reproduction. For example, hydra perform regeneration but reproduce by the method of budding. The hydra and the planarian flatworm have long served as model organisms for their highly adaptive regenerative capabilities.[9] Once wounded, their cells become activated and start to remodel tissues and organs back to the pre-existing state.[10] The Caudata ("urodeles"; salamanders and newts), an order of tailed amphibians, is possibly the most adept vertebrate group at regeneration, given their capability of … Continue reading →

Myogenesis is the formation of muscular tissue, particularly during embryonic development. Muscle fibers generally form the fusion of myoblasts into multi-nucleated fibers called myotubes. In the early development of an embryo, myoblasts can either proliferate, or differentiate into a myotube. What controls this choice in vivo is generally unclear. If placed in cell culture, most myoblasts will proliferate if enough fibroblast growth factor (FGF) or another growth factor is present in the medium surrounding the cells. When the growth factor runs out, the myoblasts cease division and undergo terminal differentiation into myotubes. Myoblast differentiation proceeds in stages. The first stage, involves cell cycle exit and the commencement of expression of certain genes. The second stage of differentiation involves the alignment of the myoblasts with one another. Studies have shown that even rat and chick myoblasts can recognise and align with one another, suggesting evolutionary conservation of the mechanisms involved.[1] The third stage is the actual cell fusion itself. In this stage, the presence of calcium ions is critical. In mice, fusion is aided by a set of metalloproteinases called meltrins and a variety of other proteins still under investigation. Fusion involves recruitment of actin to the plasma membrane, followed by … Continue reading →

DEB Laboratory Research Aims: We broadly investigate mechanisms of cardiac repair and regeneration and in particular study the interface of scar forming cells and cardiac progenitors in regulating a cardiac injury response. We use a variety of genetic, molecular and physiologic approaches to study how the outcome of a repair response can be manipulated to minimize scarring and enhance cardiac function. Main projects in the lab are summarized below: The heart is unable to regenerate heart muscle after a heart attack and lost cardiac muscle is replaced by scar tissue. Scar tissue does not contribute to cardiac contractile force and the remaining viable cardiac muscle is thus subject to a greater hemodynamic burden. Over time, the heart muscle eventually fails leading to the development of heart failure and 500,000 patients are diagnosed annually in the United States with heart failure. Thus the inability of the heart to regenerate cardiac muscle, coupled with a predominant fibrotic injury response remain major fundamental obstacles to treating heart disease. Our laboratory studies the interface of cardiac fibroblasts (scar forming cells) and cardiac progenitors in determining how a cross talk between these cells regulates cardiac repair. We use murine models of cardiac injury and use … Continue reading →

References Allen RE, Sheehan SM, Taylor RG, Kendall TL and Rice GM (1995) Hepatocyte growth factor activates quiescent skeletal muscle satellite cells in vitro. Journal of Cellular Physiology 165: 307312. Ausoni S and Sartore S (2009) From fish to amphibians to mammals: in search of novel strategies to optimize cardiac regeneration. Journal of Cell Biology 84: 357364. Brockes JP and Kumar A (2008) Comparative aspects of animal regeneration. Annual Review of Cell and Developmental Biology 24: 525549. Carlson BM (1973) The regeneration of skeletal muscle: a review. American Journal of Anatomy 137: 119150. Carlson BM (1979) Relationship between the tissue and epimorphic regeneration of skeletal muscle. In: Mauro A (ed.) Muscle Regeneration, pp. 5772. New York: Raven Press. Carlson BM (2003) Muscle regeneration in amphibians and mammals: passing the torch. Developmental Dynamics 226: 167181. Carlson BM (2008) Muscle regeneration in animal models. In: Schiaffino S and Partridge TA (eds) Skeletal Muscle Repair and Regeneration, pp. 163179. The Netherlands: Springer. Corselli M, Chen CW, Crisan M, Lazzari L and Pault B (2010) Perivascular ancestors of adult multipotent stem cells. Arteriosclerosis, Thrombosis, and Vascular Biology 30: 11041109. Dhawan J and Rando TA (2005) Stem cells in postnatal myogenesis: molecular mechanisms of satellite … Continue reading →